Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Lease liabilities — Non-current by Quarter
Lease liabilities — Non-current ($M) ($M)
Moderna Lease liabilities — Non-current: $644M in Q2 2026, down 7.7% from a year earlier.
Latest, Q2 2026
644
Period ended Jun 30, 2026
Change on a year earlier
-7.7%
698 in Q2 2025
History
28 quarters
Since Q4 2018
Sources
27
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 10 (Leases).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lease liabilities — Non-current ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 644 | -7.7% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 658 | -6.3% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 673 | -5.2% | Form 10-Q (filed 2026-07-31) ↗ |
| Q3 2025 | Sep 30, 2025 | 686 | -47.4% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 698 | -43.9% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 702 | -42.1% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 710 | -41.7% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,304 | +2.5% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,244 | +31.4% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,212 | +30.7% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,218 | +21.3% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,272 | +27.1% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 947 | +30.1% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 927 | +25.1% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,004 | +42.4% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,001 | +191.8% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 728 | +68.1% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 741 | +216.7% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 705 | +240.6% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2021 | Sep 30, 2021 | 343 | +65.2% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 433 | +158.0% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 234 | +58.3% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 207 | +56.3% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 208 | – | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 168 | – | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 148 | – | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 132 | +29.8% | Form 10-K (filed 2021-02-26) ↗ |
| Q4 2018 | Dec 31, 2018 | 102 | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Moderna Lease liabilities — Non-current ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/tot-lease-liab-nc
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.